Taysha Gene Therapies, Inc. TSHA

4.67 (0.12) (2.51%) as of 25 Sep
Market cap
$1.6B
P/E
0.0×

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Net Income

+8 more TTM periods

(99.93) (108.99) (129.88) (149.63)
Depreciation & Amortization
1.15 1.15 1.16 1.17
Non Cash Items (Other)
15.00 20.13 22.24 19.20
Accounts Payable Change
0.47 (0.15) 0.21 1.77
Change in payables and accrued liability
3.72 6.29 3.27 3.39
Change in other assets and liabilities
(5.09) (11.51) (8.95) (8.09)
Operating Cash Flow
(84.68) (93.09) (111.95) (132.19)
Capital expenditures
(0.49) (0.74) (0.38) (0.38)
Change in intangibles (net)
— — (6.50) (6.50)
Other investing activities
0.14 0.13 — —
Investing cash flow
(0.34) (0.60) (3.26) (3.32)
Repayment/Issuance of Debt (Net)
45.75 15.77 — —
Equity Repurchase (Common, Net)
215.67 265.69 266.30 266.71
Other financial activities
(0.24) (0.34) (0.19) (0.23)
Financing cash flow
224.68 274.59 275.35 275.72
Change in Cash
139.66 180.90 160.15 140.21
Beginning Cash
141.64 141.64 322.53 322.53
Ending Cash
281.29 322.53 482.68 462.74
Stock Based Compensation
12.99 13.30 15.55 18.17
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(0.90) (5.37) (5.47) (2.92)
Issuance/Purchase of Shares
215.67 265.69 266.30 266.71

Fold the line items

In millions of $ except per-share values · columns are period end dates